A Walyering spin off? Dunno. My appraisal of the STX offer is that Walyering was the only target, they didn't want to pay for our other PB assets and I have said for months that Gurvantes was our insurance policy against TO. Maybe STX just underestimated the messiness/cost of the Gurvantes spinoff, I have tried to think of a smart, cost effective way of doing it but TBH, I just don't think there is one.
- Forums
- ASX - By Stock
- TPD
- Colby's Response to STX Offer
Colby's Response to STX Offer, page-254
-
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TPD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online